




RealRate

PHARMACEUTICAL 2020

Harrow INC
Rank 172 of 363



HARROW
Your patients. Our purpose.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Harrow INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Harrow INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Harrow INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 16% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	36,767
Cost of Goods Sold	16,749
Intangible Assets	2,669
Liabilities, Current	12,284
Liabilities, Non-Current	6,338
Other Assets	14,274
Other Compr. Net Income	0
Other Expenses	4,040
Other Liabilities	13,045
Other Net Income	4,678
Other Revenues	51,165
Property and Equipment	5,375
Research and Development	2,083
Selling, General and Administrative Expense	33,096

Output Variable	Value in 1000 USD
Assets	59,085
Liabilities	31,667
Expenses	55,968
Revenues	51,165
Stockholders Equity	27,418
Net Income	-125
Comprehensive Net Income	-125
BaseVar	101,282
ECR before Limited Liability	131%
Economic Capital Ratio	254%